1. Home
  2. > Pharmaceutical
  3. > OTC Market Trends
Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Pharmacotherapy and Disease Type

Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Pharmacotherapy and Disease Type

  • October 2022
  • 209 pages
  • ID: 6362997
  • Format: PDF
  • The Insight Partners


Table of Contents

Search Inside

The global overactive bladder treatment market is expected to grow from US$ 4,295.93 million in 2021 to US$ 5,333.92 million by 2028. It is estimated to grow at a CAGR of 3.1% from 2022 to 2028.

Overactive bladder (OAB) is the frequent and sudden urge to urinate, which might be difficult to control.OAB can be caused due to abdominal trauma, infection, nerve damage, and certain medications.

OAB is common in people aged 65 and older.Women may have OAB after 45 years.

The treatment includes changing certain behaviors, medications, and nerve stimulation.According to the National Association for Incontinence data, in 2018, ~200 million people worldwide were affected by urinary incontinence.

Stress incontinence and urge incontinence are the two common types of urinary incontinence affecting women, wherein the latter is also known as overactive bladder.

Similarly, a study conducted by a group of researchers at the American College of Physicians and Infectious Diseases Society of America in 2020 stated that urinary tract infection (UTI) was the cause of ~6 million physician visits each year in the US.In Canada, ~500,000 visits to the doctor’s office are for UTI consultations annually.

UTI is the eighth and fifth most common reason for ambulatory clinic visits and emergency department visits, respectively, in the country. Thus, increasing prevalence of urinary incontinence and growing incidence of urinary tract infections are driving the overactive bladder treatment market.

The overactive bladder treatment market is segmented into pharmacotherapy, disease type, and geography.By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America.

The overactive bladder treatment market report offers insights and in-depth analysis of the market, emphasizing parameters, such as market trends, market dynamics, and the competitive analysis of the globally leading market players.

Based on pharmacotherapy, the overactive bladder treatment market is segmented into mirabegron, Botox, neurostimulation, anticholinergics, and intravesical instillation.The mirabegron segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR during the forecast period.

Mirabegron is used alone or with solifenacin to treat overactive bladder in adults.It is used to treat neurogenic detrusor overactivity (a bladder control condition caused by the brain, spinal cord, or nerve problem) in children aged three years or more.

Mirabegron belongs to the class of drugs called beta-3 adrenergic agonists.It relaxes the bladder muscles to prevent urgent, frequent, or uncontrolled urination.

Mirabegron is available as an extended-release (long-acting) tablet and an extended-release suspension that can be taken orally. In October 2022, Zydus Pharmaceuticals Inc. received approval from the USFDA to market Mirabegron Extended-Release Tablets USP 25 mg and 50 mg.

The COVID-19 pandemic has shown some favorable scenarios for players operating in the overactive bladder treatment market.The US was the highly affected country in North America.

The infection severely affected the geriatric population in the country, causing various complications and leading to the death of a large population.For instance, as of May 16, 2022, the US reported 84,230,829 COVID cases with 1,026,670 deaths.

Therefore, overactive bladder treatment and proper care are required to prevent chronic cases of infection and health conditions.

After the COVID-19 outbreak, there has been an increase in the occurrence of OAB.According to a study by American Urological Association, patients with COVID-19 infections were at an increased risk for developing new or worsening overactive bladder symptoms.

Moreover, approximately one-third of patients with COVID-19 reported a significant increase in clinical symptoms during the International Consultation on Incontinence Questionnaire Overactive Bladder Module (ICIQ-OAB) conducted two months after infection.Out of these one-third of patients, approximately 1 in 5 patients, reported that their OAB symptoms were new.

This increased prevalence of OAB due to COVID-19 positively impacted the demand for overactive bladder treatment during the pandemic.

Some of the key primary and secondary sources referred to while preparing the report on the overactive bladder treatment market are the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and the Office on Women’s Health—a division of US Department of Health and Human Services, among others.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers


Reportlinker.com © Copyright 2023. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on